Exclusion Criteria:~1. Subjects who have a Mini Mental State Examination (MMSE) score of < 10~2. Subjects who
have serious or unstable medical conditions that would exclude completion of all procedures and data collection
for the study, or would be likely to preclude participation in a drug development trial~3. A current Diagnostic
and Statistical Manual of Mental Disorders (DSM) diagnosis of active major depression, schizophrenia or bipolar
disorder~4. Other infectious, metabolic or systemic diseases affecting the central nervous system~5. Subjects
who have participated in a clinical trial investigating an anti-amyloid agent~6. Subjects who are currently
participating in a clinical trial with an investigational drug~7. Subjects who, in the opinion of the
physician, are otherwise unsuitable for this study~8. Clinically significant, advanced or unstable disease that
may interfere with outcome measures, and which may bias the assessment of the clinical or mental status of the
subject or put the subject at special risk~9. History of or screening brain MRI scan indicative of significant
abnormality, including, but not limited to, prior hemorrhage or infarct > 1 cm3, >3 lacunar infarcts, cerebral
contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying
lesion (e.g. abscess or brain tumor such as meningioma)~10. Subject has had a myocardial infarction, unstable
angina, stroke, transient ischemic attack or required intervention for any of these conditions within 6 months
of Screening~11. Clinical or laboratory findings consistent with:~ 1. Other primary degenerative dementia,~ 2.
Other neurodegenerative condition~ 3. Seizure disorder~12. Subjects, who are already taking sedatives,
antidepressants, antipsychotics and antihistaminic medications
